JCC: Calcium-carrying protein and lipid-carrying protein 2 exactly who is better at inflammatory bowel disease in fecal biomarkers.

Fecal biomarkers, especially calcium-guard protein (FCAL), have become an important diagnostic and monitoring tool for inflammatory bowel disease (IBD).
Since FCAL is primarily produced by neutral granulocytes, we hypothesically assume that fecal lipocalin-2 (FLCN2), also expressed by intestinal endocyste cells (IEC), may be able to predict disease activity of inflammatory bowel disease in certain clinical situations.
researchers compared FCAL and FLCN2 concentrations in 132 IBD patients (72 CDs) and 40 control cohort feces, and collected the correlation between clinical and endoscopic activity in patients.
the cell origin of these biomarkers is done by making laser confocus microscopes and flow-flow cytometers.
results show an excellent correlation between FCAL and FLCN2 (RS s 0.87, p s.lt;0.001) and predict the sensitivity and specificity of clinical and endoscopic disease activity equivalent to ulcerative colitis The optimal thresholds for endoscopic activity are 73.4 and 1.98 μg / g, respectively, in Crohn's disease (CD) 78.4 and 0.56 μg /g (FCAL and FLCN2).
strong co-expression of the two proteins was observed in granulocytes and macrophages.
in the IBD queue for deep mitigation, FCAL and FLCN2 were no different from the control group.
study confirmed the diagnostic ethonsexuality of FLCN2 and FCAL in IBD.
.